Anpheros Search · Treatment

Doxorubicin

Also known as: Caelyx pegylated liposomal · Myocet liposomal (previously Myocet) · Zolsketil pegylated liposomal · Doxorubicin Hydrochloride

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, pegylated liposomal doxorubicin is indicated as monotherapy for metastatic breast cancer in patients with increased cardiac risk, for advanced ovarian cancer after failed platinum-based chemotherapy, in combination with bortezomib for progressive multiple myeloma, and for AIDS-related Kaposi's sarcoma. Liposomal doxorubicin is also indicated in the European Union in combination with cyclophosphamide for the first-line treatment of metastatic breast cancer in adult women. In the United States, doxorubicin hydrochloride is indicated as a component of multiagent adjuvant chemotherapy for women with axillary lymph node involvement following resection of primary breast cancer. Additionally, doxorubicin hydrochloride is indicated in the United States for treating acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and various metastatic cancers, including breast, Wilms' tumor, neuroblastoma, soft tissue sarcoma, bone sarcoma, ovarian, transitional cell bladder, thyroid, gastric, and bronchogenic carcinomas.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm: 3639 doxorubicin
EMA: EMEA/H/C/000089, EMEA/H/C/000297, EMEA/H/C/005320

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Caelyx pegylated liposomal

Caelyx pegylated liposomal is indicated: as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk; for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen; in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant; for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (<200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. Caelyx pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standarddoxorubicin (or other anthracycline).

Source: European Medicines Agency (EMA), Caelyx pegylated liposomal — EPAR, 24/04/2026. © European Medicines Agency.

Document date: 24/04/2026 · Official document →

FDA (USA) Doxorubicin Hydrochloride

1 INDICATIONS AND USAGE Doxorubicin hydrochloride for injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer Doxorubicin hydrochloride for injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin hydrochloride for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Data provided by the U.S. Food and Drug Administration.

Document date: 20240529 · Official document →

EMA (EU) Myocet liposomal (previously Myocet)

Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.

Source: European Medicines Agency (EMA), Myocet liposomal (previously Myocet) — EPAR, 06/06/2024. © European Medicines Agency.

Document date: 06/06/2024 · Official document →

EMA (EU) Zolsketil pegylated liposomal

Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults: • breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease; • advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working; • multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine); • Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.

Source: European Medicines Agency (EMA), Zolsketil pegylated liposomal — EPAR, 16/04/2026. © European Medicines Agency.

Document date: 16/04/2026 · Official document →

Related terms in the cited sources

Has an official indication for

Kaposi Sarcoma Condition

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Doxorubicin approved for in the European Union?

Caelyx pegylated liposomal is indicated: as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk; for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen; in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant; for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (<200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. Caelyx pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standarddoxorubicin (or other anthracycline). (Source: European Medicines Agency (EMA), Caelyx pegylated liposomal — EPAR, 24/04/2026. © European Medicines Agency.)

Sources and attribution

Data provided by the U.S. Food and Drug Administration.
Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Source: European Medicines Agency (EMA), Myocet liposomal (previously Myocet) — EPAR, 06/06/2024. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →

About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.

Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.

What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.

Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.

In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.